Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine

AIDS

Volumn 24, Issue 7, 2010, Pages 1013-1018

  Maserati, Renato ^a   De Silvestri, Annalisa ^b   Uglietti, Alessia ^a   Colao, Grazia ^c   Di Biagio, Antonio ^d   Bruzzone, Bianca ^d   Di Pietro, Massimo ^e   Re, Maria Carla ^f   Tinelli, Carmine ^b   Zazzi, Maurizio ^g  

^a Department of Infectious Disease ^*  (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g UNIVERSITY OF SIENA   (Italy)

Author keywords

Antiviral drug resistance; Emtricitabine; HAART; Lamivudine; Mutations

Indexed keywords

ABACAVIR; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NUCLEAR PROTEIN; PROTEIN K70R; PROTEIN M184V; PROTEIN T215F; PROTEIN Y181C; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNCLASSIFIED DRUG; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG HALF LIFE; DRUG RESISTANCE; FEMALE; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT FAILURE;

ADENINE; ADULT; ANALYSIS OF VARIANCE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEOXYCYTIDINE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MUTATION; PHOSPHONIC ACIDS; RETROSPECTIVE STUDIES; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD;

EID: 77950924843     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328336e962     Document Type: Article

References (20)

1. Hazen R, Lanier ER. Relative anti-HIV-1 efficacy of lamivudine and emtricitabine in vitro is dependent on cell type. J Acquir Immune Defic Syndr 2003; 32:255-258.
2. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993; 90:5653-5656.
3. Geretti AM. Clinical implications of HIV drug resistance to nucleoside and nucleotide reverse transcriptase inhibitors. AIDS Rev 2006; 8:210-220.
4. Schinazi RF, McMillanA,CannonD,MathisR,Loyd RM,Peck A, et al. Selective inhibition of human immunodeficiency viruses by racements and enantiomers of cis-5-fluoro-1-[2-(hydroxy-methyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Che-mother 1992; 36:2423-2431.
5. Schinazi RF, Lloyd RM, Nguyen M-H, Cannon CL, McMillan A, Ilksoy N, et al. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine. Antimicrob Agents Chemother 1993; 37:875-881.
6. Feng JY, Shi J, Schinazi RF, Anderson KS. Mechanistic studies show that (-)-FTC-TP is a better inhibitor of HIV-1 reverse transcriptase than 3TC-TP. FASEB J 1999; 13:1511-1517.
7. Anderson PL, Kakuda TN, Lichtenstein KA. The cellular pharmacology of nucleoside-and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxici-ties. Clin Infect Dis 2004; 38:743-753.
8. Rodriguez JF, Rodriguez JL, Santana J, Garcia H, Rosario O. Simultaneous quantitation of intracellular zidovudine and lamivudine triphosphates in human immunodeficiency virus-infected individuals. Antimicrob Agents Chemother 2000; 44:3097-3100.
9. Moore KHP, Barrett JE, Shaw S, Pakes GE, Churchus R, Kapoor A, et al. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS 1999; 13:2239-2250.
10. Wang LH, Begley J, St Claire RL 3rd, Harris J, Wakeford C, Rousseau FS. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. AIDS Res Hum Retroviruses 2004; 20:1173-1182.
11. Borroto-Esoda K, Vela JE, Myrick F, Ray AS, Miller MD. In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine. Antivir Ther 2006; 11:377-384.
12. Robbins B, Srinivas R, Kim C, Bischofberger N, Fridland A. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl) adenine (PMPA), bis (isopropyloxymethylcarbonyl) PMPA. Antimicrob Agents Chemother 1998; 42:612-617.
13. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1. Top HIV Med 2008; 16:138-145.
14. Benson CA, van der Horst C, Lamarca A, Haas DW, McDonald CK, Steinhart CR, et al. A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV. AIDS 2004; 18:2269-2276.
15. Murray RJ, Lewis FI, Miller MD, Brown AJ. Genetic basis of variation in tenofovir drug susceptibility in HIV-1. AIDS 2008; 22:1113-1123.
16. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med 2004; 350:1023-1035.
17. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavu-dine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
18. de Mendoza C, Jiménez-Nacher I, Garrido C, Barreiro P, Poveda E, Corral A, et al. Changing patterns in HIV reverse transcrip-tase resistance mutations after availability of tenofovir. Clin Infect Dis 2008; 46:1782-1785.
19. Schiller DS, Youssef-Bessler M. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV. Clin Ther 2009; 31:692-704.
20. Riddler SA, HaubrichR,DiRienzo AG, PeeplesL, Powderly WG, Klingman KL,etal. Class-sparing regimens for initialtreatment of HIV-1 infection. N Engl J Med 2008; 358:2095-2106